Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response
出版年份 2018 全文链接
标题
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response
作者
关键词
-
出版物
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-10-06
DOI
10.1111/jdv.15277
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
- (2017) Zarif K. Jabbar-Lopez et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Biologic drug survival in Israeli psoriasis patients
- (2017) Guy Shalom et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial
- (2017) J.-P. Lacour et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria
- (2016) M Inzinger et al. ACTA DERMATO-VENEREOLOGICA
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t
- (2016) J. Zweegers et al. BRITISH JOURNAL OF DERMATOLOGY
- ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice
- (2016) Eva Vilarrasa et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
- (2016) K. Reich et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
- (2016) A. Menter et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Network Meta-Analysis To Evaluate The Efficacy of Ixekizumab In The Treatment of Moderate-To-Severe Psoriasis
- (2016) S Hartz et al. VALUE IN HEALTH
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response
- (2015) J.E. Signorovitch et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
- (2015) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- The global burden of psoriatic skin disease
- (2015) K.L. Goff et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
- (2015) C. Paul et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis
- (2015) Alexander Nast et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
- (2015) Richard B. Warren et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
- (2015) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada
- (2015) Aditya K. Gupta et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network
- (2014) J.M.P.A. van den Reek et al. BRITISH JOURNAL OF DERMATOLOGY
- Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis
- (2014) S.P. Menting et al. BRITISH JOURNAL OF DERMATOLOGY
- Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
- (2014) R. Gniadecki et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
- (2014) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
- (2014) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- The economic burden of psoriasis: a systematic literature review
- (2014) Steven R Feldman et al. Expert Review of Pharmacoeconomics & Outcomes Research
- The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials
- (2013) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- Biological treatments for moderate-to-severe psoriasis: indirect comparison
- (2013) M. Galván-Banqueri et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Drug survival rates in patients with psoriasis after treatment with biologics
- (2013) Yoshinori Umezawa et al. JOURNAL OF DERMATOLOGY
- Evidence Synthesis for Decision Making 4
- (2013) Sofia Dias et al. MEDICAL DECISION MAKING
- A network meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis
- (2013) D. Odom et al. VALUE IN HEALTH
- Demystifying trial networks and network meta-analysis
- (2013) E. J. Mills et al. BMJ-British Medical Journal
- Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment
- (2012) Sonia A. Lamel et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis
- (2012) Vincent W. Lin et al. ARCHIVES OF DERMATOLOGY
- Evidence Synthesis for Decision Making 2
- (2012) Sofia Dias et al. MEDICAL DECISION MAKING
- Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials
- (2011) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
- (2011) Atsuyuki IGARASHI et al. JOURNAL OF DERMATOLOGY
- Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
- (2011) David C. Hoaglin et al. VALUE IN HEALTH
- Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial
- (2010) Hideshi Torii et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
- (2010) Akihiko ASAHINA et al. JOURNAL OF DERMATOLOGY
- The relevance of biologics for the treatment of patients with psoriasis
- (2009) Peter C.M. van de Kerkhof BRITISH JOURNAL OF DERMATOLOGY
- Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis
- (2009) Nick Bansback et al. DERMATOLOGY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More